Abstract
A specific SPRI sensor for cathepsin determination based on the interaction between immobilized cystatin and cathepsins has been developed. All cathepsins form the same calibration curve. The sensor dynamic response range is between 0.5 and 2.0 ng ml-1 and the detection limit is equal to 0.1 ng ml-1.
Keywords: Surface Plasmon Resonance Imaging, cathepsins, cystatin, biosensor, blood plasma, leukocytes
Protein & Peptide Letters
Title: Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Volume: 16 Issue: 11
Author(s): E. Gorodkiewicz
Affiliation:
Keywords: Surface Plasmon Resonance Imaging, cathepsins, cystatin, biosensor, blood plasma, leukocytes
Abstract: A specific SPRI sensor for cathepsin determination based on the interaction between immobilized cystatin and cathepsins has been developed. All cathepsins form the same calibration curve. The sensor dynamic response range is between 0.5 and 2.0 ng ml-1 and the detection limit is equal to 0.1 ng ml-1.
Export Options
About this article
Cite this article as:
Gorodkiewicz E., Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin, Protein & Peptide Letters 2009; 16 (11) . https://dx.doi.org/10.2174/092986609789353754
DOI https://dx.doi.org/10.2174/092986609789353754 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Resveratrol in the Treatment of Glioma: Insights into its Regulatory Mechanisms
Mini-Reviews in Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment
Current Drug Targets Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Physiological and Non-Redundant Functions of PKC Isotypes in T Lymphocytes
Current Immunology Reviews (Discontinued) An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Cytoskeleton-Anchoring of Conformational Mutant-Like p53, but Not Shorter Isoforms p53β and p47 (ΔN40p53) in Senescent Human Fibroblasts
Current Aging Science Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy